Factors predicting organ response in light chain amyloidosis (AL).

Authors

Surbhi Sidana

Surbhi Sidana

Mayo Clinic, Rochester, MN

Surbhi Sidana , Nidhi Tandon , Angela Dispenzieri , Morie A. Gertz , Francis Buadi , Martha Lacy , David Dingli , Amie L. Fonder , Suzanne R. Hayman , Miriam A. Hobbs , Wilson I. Gonsalves , Yi Lisa Hwa , Prashant Kapoor , Robert A. Kyle , Nelson Leung , Ronald S. Go , John Anthony Lust , Stephen J. Russell , S. Vincent Rajkumar , Shaji Kumar

Organizations

Mayo Clinic, Rochester, MN, Division of Hematology, Mayo Clinic, Rochester, MN

Research Funding

Other

Background: Organ response (OR) in AL is often delayed and difficult to predict early. Methods: We retrospectively analyzed 1308 patients (pts) with newly diagnosed AL from 2006 – 2015 to determine factors which could predict for OR. Results: Median age was 64 years (yr) and Mayo Stage was: 1 (22%); 2 (23%); 3 (25%); 4 (31%). Organ involvement was: cardiac (74%, n=932); renal (59%, n=738), liver (16%, n=205); gut (24%, n=310) and autonomic (12%, n=152). 59% (n=765) had > 1 organ involved, including 43% (n=567) with > 1 critical organ (heart, kidney, liver) involved. Treatment was: ASCT based (28%, n=330, N=1186), bortezomib based (24%, n=281), alkylator based (33%, n=392), others (5%, n=54) and none (10%). In evaluable pts, VGPR or better rates were: 53% at 6 months (m) (N=625), 72% at 12 m (N=465) and 57% overall (N=688). Table 1 lists OR at various time points. Complete OR in all involved critical organs was seen in: 51% (n=308, N=600), partial response (at least 1 OR when >1 organ involved) in 12% (n=73) and none in 37% (n=219). Complete OR was associated with better overall survival (OS) than partial or no OR (median OS: not reached vs 42 m vs 29 m; P <0.0001). In multivariate model the following variables at baseline or 1 yr mark were predictive of complete OR: lower Mayo Stage (p=0.01), fewer critical organs involved (p=0.007), higher baseline GFR (p=0.03), female sex (Complete OR 60% vs 47%; p=0.04) and VGPR at 1 yr (Complete OR 70% vs. 36%; p <0.0001). Other factors included in the model were age (p=0.9), bilirubin (p=0.1) and transplant (p=0.2). All aforementioned factors were significant in univariate analysis. Conclusions: Achievement of response in all involved critical organs is associated with better survival in AL pts than partial or no OR. Various baseline factors and VGPR at 1 yr can predict for achieving complete OR, with 70% pts who achieve VGPR at 1 yr having a complete OR.

Organ response.

Cardiac ResponseRenal ResponseLiver Response
At 6 m17% (n=88, N = 498)*31% (n=135, N=433)*#25% (n=22, N=110)*
At 12 m24% (n=123, N=504)*40% (n=167, N=421)*#26% (n=27, N=105)*
Overall OR (in evaluable pts)
Median time
50% (n=195, N=394)
7.7 m
67% (n-274, N=409)
6.4 m
43% (n=39, N=90)
5.8 m

*Including pts who died at landmark time-point #Excluding pts on dialysis at diagnosis

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Plasma Cell Disorders

Citation

J Clin Oncol 35, 2017 (suppl; abstr 8048)

DOI

10.1200/JCO.2017.35.15_suppl.8048

Abstract #

8048

Poster Bd #

374

Abstract Disclosures

Similar Abstracts

Abstract

2020 ASCO Virtual Scientific Program

Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.

First Author: Iuliana Vaxman

Abstract

2023 ASCO Annual Meeting

Management and outcomes of advanced stage cardiac AL amyloidosis in the daratumumab era.

First Author: Ariana Feuvrier-Rivera

Abstract

2020 ASCO Virtual Scientific Program

Will adding alkylating agent to bortezomib improve survival of newly diagnosed AL amyloidosis patients?

First Author: Yumeng Zhang